FGF21 and metabolic dysfunction-associated steatotic liver disease: The study recently published in the Journal of Controlled Release suggests the utilization of an albumin-fused long-acting fibroblast growth factor 21 (FGF21) analogue as a potential treatment for NAFLD, especially in obese patients who are at risk of hepatofibrosis [67].